Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 6Interventional 1

Sponsor

Cancer Type

CNS 17Endocrine 2Breast 2Thoracic 1Other hematologic neoplasm 1Other 1Lymphoid 1Head & Neck 1Genitourinary 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 5744Lung Neoplasms 3716Small Cell Lung Carcinoma 1017Breast Neoplasms 667Neoplasms 616Colorectal Neoplasms 556Melanoma 479Ovarian Neoplasms 434Neoplasm Metastasis 431Pancreatic Neoplasms 386Stomach Neoplasms 332Carcinoma, Renal Cell 311Adenocarcinoma of Lung 308Squamous Cell Carcinoma of Head and Neck 304Head and Neck Neoplasms 293Prostatic Neoplasms 284Mesothelioma, Malignant 281Esophageal Neoplasms 265Mesothelioma 244Colonic Neoplasms 225Brain Neoplasms 216Urinary Bladder Neoplasms 212Triple Negative Breast Neoplasms 209Uterine Cervical Neoplasms 207Endometrial Neoplasms 174Sarcoma 171Carcinoma, Hepatocellular 158NSCLC 134Kidney Neoplasms 127Carcinoma 127

Interventions

LY3295668 erbumine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Epilepsy × Thoracic × Clear all
NCT03898791 2021-08-05

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Eli Lilly and Company

Phase 1 Completed
48 enrolled
Thoracic

Epilepsy, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡